Browse every story filed under this topic, curated from trusted publishers around the world.
What You Should Know GoodRx has launched access to self-pay pricing for Novo Nordisk’s Ozempic® pill (oral semaglutide) for patients with type 2 diabetes. Eligible patients can obtain the medication for as low as $149 per …
Read full story →
What You Should Know Spring Health has successfully closed its acquisition of Alma, a membership platform for independent clinicians. The …
Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug …
Rapid City (S.D.) Medical Center joined Monument Health, a Rapid City-based community health system, on May 1. The two parties …
"We sincerely apologize for this oversight." The post New England Journal of Medicine Retracts Paper Because Photo of Patient’s Insides …
Memorial Hermann Health System in Houston is launching new AI-enabled remote care services through a partnership with Cadence to support …
A new peer-reviewed study found AI diagnosed emergency patients more accurately than human doctors. Researchers believe it could reshape the …
Auvelity targets the NMDA and sigma-1 receptors, providing the first non-antipsychotic treatment option for Alzheimer’s patients with agitation. The post …
Michigan Medicine is notifying about 551 patients of a privacy incident involving unauthorized access to medical information through a national …
Boston-based Beth Israel Deaconess Medical Center researchers have found GLP-1 drugs were associated with fewer peptic ulcer diagnoses among patients …
A common mechanism for reversing metabolic disease in some patients seems to be the sustained flattening of the hills and …
The scheme encourages staff and families to seek an urgent second opinion if they fear a patient's condition is worsening.
What You Should Know ECRI, a nonprofit patient safety organization, submitted formal recommendations to the House Energy and Commerce Subcommittee …
After two years, there was an 87% reduction in death in ALS patients treated with Corcept's dazucorilant compared with those …
Bambusa Therapeutics has completed patient enrolment in its Phase Ib/IIa trial evaluating BBT001 to treat moderate-to-severe atopic dermatitis. The post …
Merck KGaA has dosed the first patient in its Phase III clinical programme, evaluating enpatoran in individuals with lupus who …
In our series The Cost of Denial NBC News’ Vicky Nguyen reports on the Ohio hospital employee whose heart surgery …
What You Should Know Greatly Health raised a $4 million seed round co-led by Pear VC and Commonweal Ventures to …
What You Should Know AiZtech Labs has officially launched iSelfie BioSignals in the U.S., a smartphone-based platform that detects digital …
Digital health initiatives have reshaped how healthcare organizations deliver care, manage operations, and engage patients — but not always in …
You've seen all articles for #patients.
Check back
soon
for new stories.